BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Overview
USA - NASDAQ:BCLI - US10501E3009 - Common Stock
BCLI Key Statistics, Chart & Performance
The current stock price of BCLI is 1.17 USD. In the past month the price decreased by -1.68%. In the past year, price decreased by -77.48%.
BCLI Latest News, Press Relases and Analysis
BCLI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.47 | 401.66B | ||
| AMGN | AMGEN INC | 13.37 | 156.98B | ||
| GILD | GILEAD SCIENCES INC | 15.43 | 148.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.84 | 107.88B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.65 | 69.88B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.11B | ||
| ARGX | ARGENX SE - ADR | 88.59 | 50.23B | ||
| INSM | INSMED INC | N/A | 40.51B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.98 | 34.00B | ||
| NTRA | NATERA INC | N/A | 26.82B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.30B | ||
| BIIB | BIOGEN INC | 9.46 | 22.20B |
Related stock screener links
About BCLI
Company Profile
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 27 full-time employees. The company went IPO on 2003-05-28. The firm is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The firm's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.
Company Info
BRAINSTORM CELL THERAPEUTICS
1325 Avenue Of Americas, 28th Floor
New York City NEW YORK 10019 US
CEO: Chaim Lebovits
Employees: 27
Phone: 12014880460
BRAINSTORM CELL THERAPEUTICS / BCLI FAQ
What does BRAINSTORM CELL THERAPEUTICS do?
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 27 full-time employees. The company went IPO on 2003-05-28. The firm is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The firm's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.
What is the current price of BCLI stock?
The current stock price of BCLI is 1.17 USD. The price decreased by -2.5% in the last trading session.
Does BCLI stock pay dividends?
BCLI does not pay a dividend.
What is the ChartMill rating of BRAINSTORM CELL THERAPEUTICS stock?
BCLI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about BRAINSTORM CELL THERAPEUTICS (BCLI) stock?
7 analysts have analysed BCLI and the average price target is 15.47 USD. This implies a price increase of 1222.51% is expected in the next year compared to the current price of 1.17.
What is the employee count for BCLI stock?
BRAINSTORM CELL THERAPEUTICS (BCLI) currently has 27 employees.
What is the outstanding short interest for BRAINSTORM CELL THERAPEUTICS?
The outstanding short interest for BRAINSTORM CELL THERAPEUTICS (BCLI) is 4.2% of its float.
BCLI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BCLI. When comparing the yearly performance of all stocks, BCLI is a bad performer in the overall market: 91.02% of all stocks are doing better.
BCLI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BCLI. Both the profitability and financial health of BCLI have multiple concerns.
BCLI Financial Highlights
Over the last trailing twelve months BCLI reported a non-GAAP Earnings per Share(EPS) of -2.07. The EPS increased by 21.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -310.45% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCLI Forecast & Estimates
7 analysts have analysed BCLI and the average price target is 15.47 USD. This implies a price increase of 1222.51% is expected in the next year compared to the current price of 1.17.